The global metabolomics market size was valued at USD 4.14 billion in 2025 and is projected to grow from USD 4.75 billion in 2026 to USD 14.4 billion by 2034 at a CAGR of 14.85% during the forecast period 2026-2034.
The increase in market share during the forecast period is related to Metabolomics plays a major role in personalized medicine, which is gaining popularity and uses it to create specific treatment plans.
Metabolomics is a branch of omics sciences that deals with the study of biochemical processes, which involves the study of intermediates and byproducts of metabolic activities. These products from the metabolic pathways are called metabolomes, which includes the cluster of all metabolites involved in various body functions such as metabolic intermediates, signaling molecules, secondary metabolites, and hormones. Scientifically, a metabolomic study involves various analytical techniques (spectroscopy, chromatography, and bioinformatics) and statistical tools (multivariate analysis for the determination and study of metabolites). The study of these metabolites can help in a wide range of applications, such as substantial equivalence testing, phenotyping of genetically modified plants, identification of gene function, and study of biotic-abiotic stress reaction. enhancements in patient care will ultimately serve as a testament to the use of metabolomics in precision medicine.
Metabolomics plays a crucial role in the advancement of personalized medicine by providing in-depth information on an individual's metabolic profile. This enables accurate diagnosis, selection of treatment, and customized healthcare strategies. The rising prevalence of chronic illnesses such as diabetes, cardiovascular ailments, and cancer is driving the need for metabolomics. This method facilitates the early identification, evaluation of risk, and surveillance of various illnesses through the analysis of metabolic biomarkers driving markets growth.
Download Free Sample Report To learn more about this report,
Metabolomics has gained great traction due to its capabilities in disease biology research. In 2023, there were around 300 active clinical trials worldwide involving metabolomics techniques. This number is projected to reach 350-400 by the end of 2024. Many studies have revealed, the optimum level of specific metabolites can associate with the onset/progression of diseases. The metabolomic studies can be used to understand the response to treatment for such metabolite-related diseases. With the rapidly-rising prevalence and associated fatality-chronic lifestyle diseases, such as cancer and CVDs, researchers take increased efforts to develop novel therapeutic approaches using metabolomic tools.
Further, it is facilitating researchers and scientists to estimate physiological effects and monitor the adverse drug reactions. Thus, many pharmaceutical and biotech companies, research institutes have a huge capital for metabolomic researches. As reported by The Metabolomics Innovation Centre (TMIC), metabolomics research has experienced tremendous growth during the past decade. Thus, this extensive usage has fueled the market to achieve steady growth during the forecast period.
The metabolomics market has wide-scale applications in numerous domains. The US National Institutes of Health (NIH) funded about 500 metabolomics-related projects in 2023. This is expected to increase to approximately 550 projects in 2024. The notable research improvements supported by the market products and tools have generated awareness and support from several governments and private funding authorities across the globe.
Thus, the market has recently witnessed increased funding opportunities, which positively influences the market growth. A strong interest in metabolomics has also been demonstrated by the private sector, with businesses and venture capitalists funding both new and established businesses that focus on metabolomic analysis. The introduction of private money has expedited the advancement of novel technologies and broadened the scope of the market.
Nuclear magnetic resonance (NMR) spectrometers and mass spectrometers (MS) are two examples of the sophisticated analytical tools used in metabolomics. Global sales of metabolomics instruments reached approximately 5,000 units in 2023. Projections suggest this could increase to 5,500-6,000 units in 2024. Certain research groups may find it difficult to acquire and sustain these technologies due to their high cost. Specific knowledge and training are needed to operate and analyze data from these instruments. More widespread adoption may be hampered by the small pool of highly qualified workers.
Regulations pertaining to metabolomics applications are still changing, especially in fields like diagnostics and biomarker identification. The commercialization of solutions based on metabolomics may be impeded by this uncertainty. Regulatory organizations place a strong emphasis on data validation and repeatability when authorizing tests based on metabolomics. Developing strong validation procedures is still a difficulty.
Metabolomics provides an effective means of determining distinct metabolite patterns linked to particular diseases. In 2023, metabolomics techniques contributed to the identification of about 200 new potential biomarkers. Estimates suggest this could rise to 230-250 new potential biomarkers in 2024. This can help in the creation of early-stage, non-invasive diagnostic tests for a number of illnesses, including neurological disorders, metabolic diseases, and cancer. Knowing a person's distinct metabolic profile might help develop medicines and treatment programs that are specifically catered to their requirements. Metabolomics can be utilized to find possible biomarkers of toxicity or therapeutic response, as well as to evaluate the effectiveness of novel medications. By the end of 2023, there were about 20 FDA-approved metabolomics-based diagnostic tests. This number is expected to reach 25-30 by the end of 2024.
Request Customizationto receive a tailored report.
Bioinformatics Tools and Databases is the market leader. Among the growth factors are More potent bioinformatics tools for data analysis and metabolite identification, which are being produced by developments in machine learning and artificial intelligence (AI). Researchers can use scalable and reasonably priced data analysis and storage resources as cloud computing solutions proliferate. Enhanced endeavors to standardize data and create open-source databases foster collaboration and propel the bioinformatics industry's growth. Specific techniques, such as high-performance liquid chromatography (HPLC), divide metabolites according to size, polarity, or charge characteristics. This method divides metabolites according to size and charge using an electric field.
Analytical techniques in metabolomics are the methods used to separate, identify, and measure metabolites in biological samples. This division often contains techniques like chromatography (liquid chromatography, gas chromatography) and spectroscopy (mass spectrometry, nuclear magnetic resonance spectroscopy). Mass spectrometry (MS) is frequently used because of its sensitivity and ability to evaluate various metabolites. Mass spectrometry is preferred in metabolomics because it can identify and quantify a wide range of metabolites with high sensitivity and specificity, making it essential for complete metabolomic profiling.
The Biomarker and Drug Discovery application category is leading the Metabolomics market. The rise in the prevalence of chronic diseases, the need for more individualized healthcare, and technological developments in discovery technologies are the leading causes of this market's importance. Furthermore, the expansion of this market has been facilitated by the acceptance of contemporary diagnostic testing.
The customized medicine market is expected to develop at the most significant compound annual growth rate. There are other reasons why this particular section is leading: One of the primary motivators is the requirement for precise and non-invasive disease indicators. A promising method for finding biomarkers linked to a range of illnesses, including cancer, neurological conditions, and metabolic diseases, is metabolomics. Metabolomics can evaluate the effectiveness of pharmaceuticals, find putative biomarkers for toxicity or response, and streamline the drug development process. Established The market is being driven ahead by the well-established discipline of biomarker and drug discovery, which is receiving substantial funding and continuous research efforts.
The cancer category in the Metabolomics market has the most significant market share. With a high disease burden, cancer is a global health concern. Effective treatment and early detection are still substantial obstacles. Discovering new cancer biomarkers could lead to earlier diagnosis and more individualized treatment plans because of metabolomics. Metabolomics is being applied to cancer research. This means there will be a more significant market for the goods and services in this industry. Metabolomics has applications in several areas of cancer research, such as medication development, biomarker identification, therapy response monitoring, and evaluation of personalized medicine strategies. For several reasons, this market is anticipated to grow at the quickest rate.
Cardiovascular Disorders investigates the metabolic alterations linked with cardiovascular disorders such as heart disease, hypertension, and atherosclerosis. While essential, cardiovascular illnesses are often regarded as subdominant when compared to cancer in the metabolomics market. Metabolomics in cardiovascular disorders aims to understand better metabolic pathways contributing to disease progression, uncover novel biomarkers for early detection, and create tailored therapeutics to reduce cardiovascular risk factors.
Academic and Research Institutes are leading the key end-users in the Metabolomics market. Universities and research institutes dominate the market because they play a significant role in metabolomics research, which is crucial for advancing the discipline and finding new biomarkers and therapeutic targets. Companies in the biotechnology and pharmaceutical industries are also vital since they use metabolomics for precision medicine and drug development.
Speak to an Analystto discuss market opportunities.
North America is the most significant market shareholder and is estimated to grow at a CAGR of 13% over the forecast period. North America, led by the United States, has emerged as the central region in the global Metabolomics market. In 2023, nearly 40% of all metabolomics research papers came from North American institutions. The National Institutes of Health (NIH) in the United States reported financing more than 500 metabolomics-related research projects in 2023, predicted to rise to over 550 by 2024. The presence of crucial metabolomics technology vendors and research facilities demonstrates the region's supremacy. In 2023, North American clients accounted for approximately 65% of global metabolomics equipment sales.
Furthermore, in 2023, the Metabolomics Society stated that 45% of its members were headquartered in North America. Canada's contribution to the area has also been significant, with Canadian researchers accounting for around 15% of international metabolomics collaborations by 2023. The US Food and Drug Administration (FDA) approved five metabolomics-based diagnostic tests in 2023, expecting this number to climb to 7-8 by the end of 2024. This regulatory backing, combined with significant private and public financing, helps to cement North America's leadership in metabolomics
Europe is the sub-dominant region in the worldwide Metabolomics market, led by Germany, the United Kingdom, and France. In 2023, European institutions accounted for over 35% of global metabolomics research publications. The European Commission's Horizon Europe program awarded around Euros 150 million to metabolomics-related research projects in 2023, which is likely to rise to Euros 170 million by 2024. The European Molecular Biology Laboratory (EMBL) revealed that its metabolomics facilities supported over 200 research groups across Europe in 2023, with the number expected to rise to 230 by 2024.
Additionally, in terms of industry engagement, European clients accounted for approximately 30% of total global metabolomics instrument sales in 2023. The European Federation of Clinical Chemistry and Laboratory Medicine reported that by 2023, around 40% of its member laboratories were adopting metabolomics techniques in clinical diagnosis, with that figure predicted to rise to 45% by 2024. While Europe lags slightly behind North America, the region's solid academic research foundation, expanding corporate involvement, and increasing integration of metabolomics in healthcare systems continue to propel it forward in the global metabolomics landscape.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com